Assyro AI

Orange Book product · Brand (NDA)

VIBERZI

ELUXADOLINE

Brand (NDA)NDA 206940TE ABRX ABBVIE

At a glance

May 27, 2015

Approved

Brand (NDA)

Application

AB

TE code

14

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    May 27, 2015

    11 yr 3 mo ago

  2. Today

  3. Patent 8691860 expires

    Listed drug substance patent expiration.

    Jul 07, 2028

    in 2 yr 1 mo

  4. Patent 9115091 expires

    Listed drug substance patent expiration.

    Jul 07, 2028

    in 2 yr 1 mo

  5. Patent 9364489 expires

    Listed method-of-use patent (U-1709) expiration.

    Jul 07, 2028

    in 2 yr 1 mo

  6. Patent 9789125 expires

    Listed drug product patent expiration.

    Jul 07, 2028

    in 2 yr 1 mo

  7. Patent 9789125 expires

    Listed drug product patent expiration.

    Jul 07, 2028

    in 2 yr 1 mo

  8. Patent 7741356 expires

    Listed drug substance patent expiration.

    May 27, 2029

    in 3 yr

  9. Patent 10188632 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  10. Patent 11007179 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  11. Patent 11090291 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  12. Patent 11160792 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  13. Patent 11229627 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  14. Patent 11311516 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  15. Patent 12097187 expires

    Listed method-of-use patent (U-3475) expiration.

    Mar 14, 2033

    in 6 yr 10 mo

  16. Patent 9675587 expires

    Listed drug product patent expiration.

    Mar 14, 2033

    in 6 yr 10 mo

Pharmaceutical detail

Active ingredient

ELUXADOLINE

Strength

75MG

Dosage form

TABLET

Route

ORAL

TE code

AB

Application

NDA 206940

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (14)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8691860Jul 07, 2028in 2 yr 1 mo
SubstanceU-1709
9115091Jul 07, 2028in 2 yr 1 mo
SubstanceProductU-1738
9364489Jul 07, 2028in 2 yr 1 mo
U-1709
9789125Jul 07, 2028in 2 yr 1 mo
ProductU-2152
9789125Jul 07, 2028in 2 yr 1 mo
ProductU-1709
7741356May 27, 2029in 3 yr
SubstanceProduct
10188632Mar 14, 2033in 6 yr 10 mo
Product
11007179Mar 14, 2033in 6 yr 10 mo
Product
11090291Mar 14, 2033in 6 yr 10 mo
Product
11160792Mar 14, 2033in 6 yr 10 mo
Product
11229627Mar 14, 2033in 6 yr 10 mo
Product
11311516Mar 14, 2033in 6 yr 10 mo
Product
12097187Mar 14, 2033in 6 yr 10 mo
U-3475
9675587Mar 14, 2033in 6 yr 10 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.